BTX BioTime Inc.

1.42
-0.14  -9%
Previous Close 1.56
Open 1.52
Price To Book 2.25
Market Cap 211345710
Shares 149,360,926
Volume 930,152
Short Ratio 7.4
Av. Daily Volume 1,122,067

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trial data released June 14, 2017 - primary endpoint met.
Renevia
Restoring normal skin contours in for patients with HIV
Phase 1 data due 2019 and 2020.
AST-VAC2
Non-small cell lung cancer (NSCLC)
Phase 1/2 12-month data from cohorts 3 and 4 released July 31, 2018. Intends to meet with FDA regarding next steps.
AST-OPC1 SCiSTAR
Cervical spinal cord injury
Phase 1/2 enrolment to be completed 2019. Updated data due April 30, 2019 at Ophthalmology Annual Meeting.
OpRegen
Dry age-related macular degeneration (AMD)
Phase 2b planned for 2018.
AST-VAC1
Maintenance of relapse-free-survival in acute myeloid leukemia (AML)

Latest News

  1. Edited Transcript of BTX earnings conference call or presentation 14-Mar-19 8:30pm GMT
  2. BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019
  3. BioTime: 4Q Earnings Snapshot
  4. BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
  5. BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company
  6. BioTime to Report Fourth Quarter and Full Year 2018 Financial Results on March 14th, 2019
  7. BioTime to Present at the 14Th Annual Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT 2019) on March 10, 2019
  8. BioTime to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
  9. Consolidated Research: 2019 Summary Expectations for Walmart, W.R. Grace, BioTime, Genesee & Wyoming, Northrop Grumman, and Versum Materials — Fundamental Analysis, Key Performance Indications
  10. BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias
  11. Most Intriguing Companies on the New LD Micro Index
  12. BioTime Inc. Affiliate Company OncoCyte Corporation Reports Successful Results With DetermaVu™ Diagnostic Test for Lung Cancer
  13. Today's Research Reports on Trending Tickers: BioTime and Zynerba Pharmaceuticals
  14. AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity
  15. BioTime Enters Into Exclusive Agreement With Orbit Biomedical Ltd. to Access Innovative Device for the Sub-Retinal Delivery of OpRegen® Cells for the Treatment of Dry-AMD
  16. BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase
  17. BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019
  18. AgeX Therapeutics to Present at Biotech Showcase 2019
  19. BioTime, Inc. (BTX): Are Hedge Funds Right About This Stock?
  20. BioTime Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem® Platform in Ischemic Stroke